Profile data is unavailable for this security.
About the company
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).
- Revenue in USD (TTM)72.65m
- Net income in USD19.84m
- Incorporated2000
- Employees46.00
- LocationMEI Pharma Inc11455 El Camino Real, Suite 250SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 369-7100
- Fax+1 (302) 655-5049
- Websitehttps://www.meipharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galecto Inc | 0.00 | -30.83m | 18.98m | 13.00 | -- | 0.6741 | -- | -- | -1.15 | -1.15 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -63.50 | -48.46 | -78.33 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
| KALA BIO Inc | 0.00 | -42.20m | 19.74m | 43.00 | -- | 2.58 | -- | -- | -17.94 | -17.94 | 0.00 | 2.72 | 0.00 | -- | -- | 0.00 | -59.12 | -57.83 | -77.62 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -12.78 | 0.82 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.03m | 20.30m | 3.00 | -- | 3.84 | -- | -- | -0.0176 | -0.0176 | 0.00 | 0.0307 | 0.00 | -- | -- | 0.00 | -28.92 | 27.48 | -30.91 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 20.32m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| MEI Pharma Inc | 72.65m | 19.84m | 20.39m | 46.00 | 1.03 | 0.3427 | 1.01 | 0.2807 | 2.98 | 2.98 | 10.90 | 8.93 | 0.6425 | -- | 25.47 | 1,579,304.00 | 17.55 | -25.31 | 20.31 | -28.59 | -- | -- | 27.32 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
| Evaxion Biotech A/S - ADR | 73.00k | -22.13m | 20.60m | 49.00 | -- | -- | -- | 282.18 | -81.29 | -81.29 | 0.2665 | -1.25 | 0.0042 | -- | 0.091 | 1,489.80 | -126.74 | -100.11 | -183.85 | -131.65 | -- | -- | -30,308.22 | -131,560.30 | -- | -30.92 | 1.77 | -- | -- | -- | 4.51 | -- | 65.53 | -- |
| AIM ImmunoTech Inc | 202.00k | -28.96m | 20.60m | 26.00 | -- | 2.08 | -- | 101.98 | -0.595 | -0.595 | 0.0042 | 0.2084 | 0.0068 | -- | 0.1413 | 7,769.23 | -96.75 | -45.64 | -116.18 | -48.35 | 79.21 | -231.75 | -14,337.62 | -11,695.01 | -- | -- | 0.00 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| Serina Therapeutics Inc | 142.00k | -14.80m | 20.76m | 4.00 | -- | 1.64 | -- | 146.17 | -13.72 | -13.72 | 0.1316 | 5.07 | 0.0187 | -- | 4.66 | 35,500.00 | -194.80 | -194.46 | -- | -- | 71.83 | 85.80 | -10,430.28 | -2,347.36 | -- | -2.03 | 0.4489 | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
| Alaunos Therapeutics Inc | 5.00k | -35.14m | 20.82m | 1.00 | -- | 3.30 | -- | 4,163.25 | -2.20 | -2.20 | 0.0003 | 0.3939 | 0.0001 | -- | 2.00 | 5,000.00 | -96.01 | -74.83 | -149.28 | -89.57 | -- | -- | -702,800.00 | -10,508.06 | -- | -14.83 | 0.00 | -- | -99.83 | -49.08 | 6.86 | -- | -15.56 | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 20.84m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Biomx Inc | 0.00 | -26.17m | 21.20m | 58.00 | -- | 5.73 | -- | -- | -0.5433 | -0.5433 | 0.00 | 0.067 | 0.00 | -- | -- | 0.00 | -74.18 | -- | -101.74 | -- | -- | -- | -- | -- | -- | -21.95 | 0.7841 | -- | -- | -- | 7.59 | -- | -- | -- |
| Synlogic Inc | 3.37m | -57.28m | 21.43m | 6.00 | -- | 0.3963 | -- | 6.36 | -11.41 | -11.41 | 0.6581 | 4.64 | 0.0362 | -- | -- | 561,833.30 | -61.46 | -40.57 | -74.45 | -43.82 | -- | -- | -1,699.26 | -3,245.93 | -- | -- | 0.00009 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
| Flora Growth Corp | 76.07m | -47.36m | 21.67m | 97.00 | -- | 2.36 | -- | 0.2848 | -6.62 | -7.97 | 10.04 | 0.7167 | 1.45 | 6.76 | 31.13 | 784,237.10 | -89.22 | -- | -130.91 | -- | 23.32 | -- | -61.35 | -- | 0.7897 | -- | 0.2317 | -- | 127.75 | -- | -1.87 | -- | -- | -- |
| TherapeuticsMD Inc | 1.30m | -7.70m | 21.68m | 1.00 | -- | 0.7403 | -- | 16.65 | -0.7466 | -1.00 | 0.1249 | 2.54 | 0.0195 | -- | -- | 1,302,000.00 | -11.51 | -53.35 | -19.23 | -111.61 | 100.00 | 86.67 | -591.32 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| OncoCyte Corp | 1.50m | -25.80m | 22.01m | 43.00 | -- | 1.07 | -- | 14.64 | -3.08 | -3.47 | 0.1869 | 3.10 | 0.0172 | -- | 1.20 | 34,953.49 | -28.41 | -35.11 | -31.93 | -39.71 | 27.48 | -- | -1,653.69 | -2,373.36 | -- | -146.07 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Data as of May 03 2024. Currency figures normalised to MEI Pharma Inc's reporting currency: US Dollar USD
45.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Anson Funds Management LPas of 31 Dec 2023 | 1.09m | 16.41% |
| Cable Car Capital LLCas of 31 Dec 2023 | 611.44k | 9.18% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 388.01k | 5.82% |
| Tang Capital Management LLCas of 31 Dec 2023 | 326.08k | 4.89% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 225.39k | 3.38% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 150.89k | 2.27% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 81.95k | 1.23% |
| Carlson Capital LPas of 31 Dec 2023 | 74.00k | 1.11% |
| Geode Capital Management LLCas of 31 Dec 2023 | 51.62k | 0.78% |
| Macquarie Investment Management Business Trustas of 31 Dec 2023 | 30.00k | 0.45% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
